Christian Clark's questions to scPharmaceuticals (SCPH) leadership • Q2 2025
Question
Christian Clark requested more granular details on the CKD launch trajectory, a breakdown of Q2 doses between CKD and heart failure, and an update on the company's cash runway and financing options.
Answer
CEO John Tucker clarified that the vast majority of Q2 doses were attributable to heart failure, as the nephrology launch only covered two months of the quarter. He reiterated that nephrologists have been faster adopters than cardiologists. Regarding the balance sheet, Tucker stated the company is 'laser focused' on reaching profitability and has access to an additional $10 million from Perceptive and $25 million in debt if needed.